Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP)’s share price fell 2.2% during trading on Monday . The stock traded as low as $11.08 and last traded at $11.24, with a volume of 289,145 shares changing hands. The stock had previously closed at $11.49.

Several research firms have commented on SCMP. Zacks Investment Research lowered shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 22nd. Roth Capital reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Wednesday, April 20th. Maxim Group reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday. Mizuho reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday. Finally, TheStreet lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 5th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $21.00.

The company has a market cap of $487.69 million and a P/E ratio of 22.6537. The stock’s 50 day moving average is $11.33 and its 200 day moving average is $12.03.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.02. The business had revenue of $47.20 million for the quarter, compared to analysts’ expectations of $44.11 million. Sucampo Pharmaceuticals’s revenue for the quarter was up 60.0% compared to the same quarter last year. During the same period last year, the company earned $0.14 earnings per share. On average, equities research analysts anticipate that Sucampo Pharmaceuticals Inc. will post $1.02 earnings per share for the current fiscal year.

Other large investors have recently made changes to their positions in the company. Systematic Financial Management LP increased its stake in shares of Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock worth $1,759,000 after buying an additional 15,590 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Sucampo Pharmaceuticals by 8.5% in the fourth quarter. GSA Capital Partners LLP now owns 219,881 shares of the biopharmaceutical company’s stock worth $3,802,000 after buying an additional 17,172 shares during the last quarter. Globeflex Capital L P increased its stake in shares of Sucampo Pharmaceuticals by 76.5% in the fourth quarter. Globeflex Capital L P now owns 65,588 shares of the biopharmaceutical company’s stock worth $1,134,000 after buying an additional 28,431 shares during the last quarter. NorthCoast Asset Management LLC purchased a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter worth about $1,130,000. Finally, Shell Asset Management Co. purchased a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter worth about $1,324,000.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.